Kalil AC, Patterson TF, Mehta AK, et al. - In view of the reported correlation of severe coronavirus disease 2019 (Covid-19) with dysregulated inflammation, researchers sought to determine the effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir by performing a double-blind, randomized, placebo-controlled trial including hospitalized adults with Covid-19. They randomized a total of 1,033 patients. All the patients were administered remdesivir (≤ 10 days) and either baricitinib (≤ 14 days) or placebo (control). Findings suggest that relative to remdesivir alone, baricitinib plus remdesivir was superior in decreasing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. Fewer serious adverse events were reported in correlation with providing the combination.